During the last five years, PRA has participated in more than 400 oncology and hematology clinical projects globally in every phase and virtually every indication, including supportive care.
Key Areas of Oncology & Hematology Expertise
The following tables summarize PRA’s clinical study and consulting experience in our key oncology and hematology indications during the last five years.
|Oncology||Number of Clinical Studies||Number of Clinical Sites||Number of Clinical Patients|
|Multiple Solid Tumors||42||515+||5,120+|
|Non-small Cell Lung Cancer||26||1,600+||6,500+|
|Renal Cell Carcinoma||4||170+||585+|
|Hematology||Number of Clinical Studies||Number of Clinical Sites||Number of Clinical Patients|
|Acute Myeloid Leukemia||6||350+||1,850|
Investigator Relations & Patient Access
PRA provides support for clinical trials at every level. Our network of global expertise, patient access and investigator alliances allows us to provide an accomplished service for oncology and hematology studies of all types.
PRA’s advantages include:
- Supportive care study experience.
- Global investigator network to provide access to nearly all geographical areas, including emergent markets such as Asia, Latin America and Eastern Europe for patient recruitment.
- Access to Citeline™ products (SiteTrove, TrialPredict and TrialTrove)—together with our internal investigator network—enables us to conduct accurate feasibility studies and more effectively recruit oncology/hematology patients to our studies. This approach results in faster study start-ups, thereby reducing overall development timelines for our sponsors.